Tenaya Therapeutics, Inc.
TNYA
$0.73
-$0.01-1.05%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.11M | 225.00K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.11M | 225.00K | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.11M | 225.00K | -- | -- | -- |
| SG&A Expenses | 5.41M | 5.45M | 5.98M | 5.57M | 6.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.01M | 20.29M | 20.78M | 20.94M | 24.08M |
| Operating Income | -20.90M | -20.07M | -20.78M | -20.94M | -24.08M |
| Income Before Tax | -43.39M | -19.27M | -20.18M | -20.28M | -23.28M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.39M | -19.27M | -20.18M | -20.28M | -23.28M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.39M | -19.27M | -20.18M | -20.28M | -23.28M |
| EBIT | -20.90M | -20.07M | -20.78M | -20.94M | -24.08M |
| EBITDA | -19.20M | -18.30M | -18.95M | -19.07M | -22.00M |
| EPS Basic | -0.20 | -0.09 | -0.12 | -0.12 | -0.14 |
| Normalized Basic EPS | -0.06 | -0.06 | -0.07 | -0.08 | -0.09 |
| EPS Diluted | -0.20 | -0.09 | -0.12 | -0.12 | -0.14 |
| Normalized Diluted EPS | -0.06 | -0.06 | -0.07 | -0.08 | -0.09 |
| Average Basic Shares Outstanding | 217.57M | 216.88M | 175.05M | 163.35M | 162.79M |
| Average Diluted Shares Outstanding | 217.57M | 216.88M | 175.05M | 163.35M | 162.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |